Co je nového v léčbě hypercholesterolemie?

Title in English New options in the treatment of hypercholesterolaemia

SOŠKA Vladimír KYSELÁK Ondřej

Year of publication 2016
Type Article in Periodical
Magazine / Source Interní medicína pro praxi
MU Faculty or unit

Faculty of Medicine

Field Cardiovascular diseases incl. cardiosurgery
Keywords hypercholesterolemia; LDL-cholesterol; statins; ezetimibe; PCSK9-inhibitors
Description Statins are the key drugs for LDL-cholesterol lowering: they have a lot of evidences that they decrease not only cholesterol, but also cardiovascular events and mortality. Second-line choice for lowering LDL-cholesterol is ezetimibe, which is intended to combination with statins. This year were published results of IMPROVE-IT study which showed that addition of ezetimibe to statin has also clinical benefit – decrease of cardiovascular events. New lipid-lowering drugs are PCSK9-inhibitors, first two of which were already approved for clinical use.

You are running an old browser version. We recommend updating your browser to its latest version.

More info